Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

388 ARTÍCULOS , VIENDO DEL 121 AL 135

Muscarinic and nicotinic acetylcholine receptor agonists: current scenario in Alzheimer's disease therapy

Verma S, Kumar A, Tripathi T, Kumar A.

J Pharm Pharmacol. 2018 Aug;70(8):985-993. doi: 10.1111/jphp.12919. Epub 2018 Apr 16.

Structural aspects of Alzheimer's disease immunotherapy targeted against amyloid-beta peptide

Cehlar O, Skrabana R, Revajova V, Novak M.

Bratisl Lek Listy. 2018;119(4):201-204. doi: 10.4149/BLL_2018_037.

Alzheimer disease: Non-pharmacological and pharmacological management of cognition and neuropsychiatric symptoms

Loi SM, Eratne D, Kelso W, Velakoulis D, Looi JC.

Australas Psychiatry. 2018 Aug;26(4):358-365. doi: 10.1177/1039856218766123. Epub 2018 Apr 19.

Benefit of Oleuropein Aglycone for Alzheimer's Disease by Promoting Autophagy

Cordero JG, García-Escudero R, Avila J, Gargini R, García-Escudero V.

Oxid Med Cell Longev. 2018 Feb 20;2018:5010741. doi: 10.1155/2018/5010741. eCollection 2018.

Accelerating Alzheimer's disease drug innovations from the research pipeline to patients

Goldman DP, Fillit H, Neumann P.

Alzheimers Dement. 2018 Jun;14(6):833-836. doi: 10.1016/j.jalz.2018.02.007. Epub 2018 Apr 18.

Cold Atmospheric Plasmas: A Novel and Promising Way to Treat Neurological Diseases

Xiong Z.

Trends Biotechnol. 2018 Jun;36(6):582-583. doi: 10.1016/j.tibtech.2018.04.003. Epub 2018 Apr 21.

ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease

Cummings JL, Cohen S, van Dyck CH, Brody M, Curtis C, Cho W, Ward M, Friesenhahn M, Rabe C, Brunstein F, Quartino A, Honigberg LA, Fuji RN, Clayton D, Mortensen D, Ho C, Paul R.

Neurology. 2018 May 22;90(21):e1889-e1897. doi: 10.1212/WNL.0000000000005550. Epub 2018 Apr 25.

Technological Solutions for Older People with Alzheimer's Disease: Review

Maresova P, Tomsone S, Lameski P, Madureira J, Mendes A, Zdravevski E, Chorbev I, Trajkovik V, Ellen M, Rodile K.

Curr Alzheimer Res. 2018;15(10):975-983. doi: 10.2174/1567205015666180427124547.

Targeting Insulin for Alzheimer's Disease: Mechanisms, Status and Potential Directions

Lee JH, Jahrling JB, Denner L, Dineley KT.

J Alzheimers Dis. 2018;64(s1):S427-S453. doi: 10.3233/JAD-179923.

Effectiveness of Anti-Dementia Drugs in Extremely Severe Alzheimer's Disease: A 12-Week, Multicenter, Randomized, Single-Blind Study

Hong YJ, Choi SH, Jeong JH, Park KW, Na HR.

J Alzheimers Dis. 2018;63(3):1035-1044. doi: 10.3233/JAD-180159.

Exercise Intervention Associated with Cognitive Improvement in Alzheimer's Disease

Cui MY, Lin Y, Sheng JY, Zhang X, Cui RJ.

Neural Plast. 2018 Mar 11;2018:9234105. doi: 10.1155/2018/9234105. eCollection 2018.

Issues in Geriatric Care: Alzheimer Disease

Kemle K, Ackermann RJ.

FP Essent. 2018 May;468:26-34.

A double-blind placebo-controlled cross-over clinical trial of DONepezil In Posterior cortical atrophy due to underlying Alzheimer's Disease: DONIPAD study

Ridha BH, Crutch S, Cutler D, Frost C, Knight W, Barker S, Epie N, Warrington EK, Kukkastenvehmas R, Douglas J, Rossor MN.

Alzheimers Res Ther. 2018 May 1;10(1):44. doi: 10.1186/s13195-018-0363-1.

Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease

Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, Sur C, Mukai Y, Voss T, Furtek C, Mahoney E, Harper Mozley L, Vandenberghe R, Mo Y, Michelson D.

N Engl J Med. 2018 May 3;378(18):1691-1703. doi: 10.1056/NEJMoa1706441.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias